Weight loss drug war heats up
Pfizer and Roche have released promising early stage results, but Novo Nordisk and Eli Lilly have a big head start.
Tag: Novo Nordisk
The advantage of economic moats
Often intangible things, moats keep customers close and protect the business.
Eli Lilly, Novo Nordisk soar with demand for weight loss drugs
Lilly has more than doubled in a year, while Denmark’s Novo Nordisk is up by two-thirds.
Weight loss drug era just starting: Analysts
Elil Lilly and Novo Nordisk have head start on market projected to hit $100B in US by 2030.
Drugmakers see booming demand for weight-loss drugs
Strong demand for Wegovy, Ozempic just scratching surface, says CEO of Novo Nordisk
Weight loss drugs Ozempic, Wegovy may be right for investors
Celebrity endorsements helping build market potential, analysts say
